{"doi":"10.1111/ajd.12185","title":"A case of abatacept associated neutrophilic dermatosis and a review of the literature","abstract":"<jats:title>Abstract</jats:title><jats:p>Abatacept is a novel biological agent that dampens the immune response by blocking the co‐stimulation of <jats:styled-content style=\"fixed-case\">T</jats:styled-content>‐cells, thus downregulating <jats:styled-content style=\"fixed-case\">T</jats:styled-content>‐cell activation. It is currently approved for the treatment of rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA</jats:styled-content>). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side‐effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti‐tumour necrosis factor (<jats:styled-content style=\"fixed-case\">TNF</jats:styled-content>) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept.</jats:p>","journal":"Australasian Journal of Dermatology","year":2014,"id":610866,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1570740,"name":"Benjamin A Wood","orcid":null,"position":1,"is_corresponding":false},{"id":1570741,"name":"Theresa Skender‐Kalnenas","orcid":null,"position":2,"is_corresponding":false},{"id":1411824,"name":"Nicola Cook","orcid":"0000-0003-4462-0116","position":3,"is_corresponding":false},{"id":1570739,"name":"Shevya Manjri Tiwari","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A case of abatacept associated neutrophilic dermatosis and a review of the literature","abstract":"<jats:title>Abstract</jats:title><jats:p>Abatacept is a novel biological agent that dampens the immune response by blocking the co‐stimulation of <jats:styled-content style=\"fixed-case\">T</jats:styled-content>‐cells, thus downregulating <jats:styled-content style=\"fixed-case\">T</jats:styled-content>‐cell activation. It is currently approved for the treatment of rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA</jats:styled-content>). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side‐effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti‐tumour necrosis factor (<jats:styled-content style=\"fixed-case\">TNF</jats:styled-content>) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept.</jats:p>","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25117161","pmcid":null,"openalex_id":"https://openalex.org/W1942316420","authors":[],"funders":[],"total_grants":0,"fwci":0.6099,"citation_percentile":0.67777451,"influential_citations":0,"citation_trend":[{"year":2014,"count":1},{"year":2017,"count":2},{"year":2018,"count":4},{"year":2019,"count":1},{"year":2021,"count":2}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fajd.12185","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.12185","host_type":"publisher"},{"url":"https://doi.org/10.1111/ajd.12185","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25117161","host_type":"repository"},{"url":"https://research-repository.uwa.edu.au/en/publications/36c0ee89-def5-4ed6-80fb-45e3e0e96609","host_type":"repository"}],"fields_of_study":["Autoimmune and Inflammatory Disorders","Autoimmune Bullous Skin Diseases","Skin Diseases and Diabetes"],"mesh_terms":["Abatacept","Drug Eruptions","Female","Humans","Middle Aged","Neutrophils","Antirheumatic Agents"],"keywords":["Abatacept","Medicine","Rheumatoid arthritis","Adverse effect","Dermatology","Tumor necrosis factor alpha","Immune system","Immunology","Internal medicine","Antibody","Rituximab","Biologics","Sweet's Syndrome","Neutrophilic Dermatosis","Paradoxical Reaction","Rheumatoid Neutrophilic Dermatosis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T12:09:12.722221Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}